BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Dec 8, 2025 • 13min
ASH 2025: Aleta Biotherapeutics' Paul Rennert shares the company's first clinical data for its CAR-T cell engager program that is meant to increase the density of CD19 on B-cell malignancies.
He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.
Dec 8, 2025 • 7min
ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.
Dec 8, 2025 • 16min
Lyell Immunopharma CEO Lynn Seely discusses her company's CD19/CD20 dual antigen CAR-T data at ASH
She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.
Dec 7, 2025 • 10min
ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS
He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.
Dec 7, 2025 • 7min
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.
Dec 7, 2025 • 18min
ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis
He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.
Dec 7, 2025 • 12min
ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants
Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, a journey through the patient experience of how this works.
Dec 7, 2025 • 11min
ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts.
She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.
Dec 6, 2025 • 12min
ASH 2025: Von Willibrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3
Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.
Dec 6, 2025 • 10min
ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T
He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.
